Drug combinations for HIV: What's new?

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 11, 2011, Pages 1001-1011

  Scourfield, Andrew ^a   Waters, Laura ^a   Nelson, Mark ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

antiretroviral; cART; HIV; individualization of therapy; novel strategy; toxicity

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; BMS 663068; CENICRIVIROC; DARUNAVIR PLUS RITONAVIR; DOLUTEGRAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ELVITEGRAVIR; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; GS 7340; INTEGRASE INHIBITOR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; RALTEGRAVIR; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE; ZINC FINGER PROTEIN;

ANEMIA; BRAIN TOXICITY; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERADICATION THERAPY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIVER TOXICITY; MONOTHERAPY; NONHUMAN; RASH; REVIEW; SIDE EFFECT; SKIN ALLERGY; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG COMBINATIONS; DRUG RESISTANCE, VIRAL; HIV; HIV INFECTIONS; HUMANS; INDIVIDUALIZED MEDICINE; INTEGRASE INHIBITORS; PROTEASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION;

EID: 80155177916     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.125     Document Type: Review

References (72)

1. Cooper D. Life and death in the cART era. Lancet 372(9635), 266-267 (2008).
2. van Sighem AI, Gras LA, Reiss P, Brinkman K, de Wolf F. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS 2010 24(10), 1527-1535 (2010).
3. UK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group. Lonγ-term probability of detecting druγ-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy. Clin. Infect. Dis. 50(9), 1275-1285 (2010).
4. DAD Study Group, Friis-Møller N, Reiss P, Sabin CA et al. Class of antiretroviral drugs and the risk of myocardial infarction. N. Engl. J. Med. 356(17), 1723-1735 (2007).
5. Vispo E, Morello J, Rodriguez-Novoa S, Soriano V. Noncirrhotic portal hypertension in HIV infection. Curr. Opin. Infect. Dis. 24(1), 12-18 (2011).
6. Vispo E, Barreiro P, Pineda JA et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir. Ther. 13(3), 429-437 (2008).
7. Béique L, Giguère P, la Porte C et al. Interactions between protease inhibitors and acid-reducing agents: a systematic review. HIV Med. 8(6), 335-345 (2007).
8. Ammassari A, Cozzi-Lepri A,Trotta MP et al. Treatment complexity and risk of virological rebound in persons receiving cART. Presented at: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA, 25-28 February 2007 (Abstract 522).
9. Thompson MA, Aberg JA, Cahn P et al. Antiretroviral treatment of adult HIV infection - 2010 recommendations of the IAS-USA Panel. JAMA 304(3), 321-333 (2010).
10. Gallant JE, DeJesus E, Arribas JR et al. Tenofovir DF, emtricitabine and efavirenz vs. zidovudine, lamivudine and efavirenz for HIV. N. Engl. J. Med. 354, 251-260 (2006).
11. Arribas J, Pozniak A, Gallant J et al. Three-year safety and efficacy of emtricitabine (FTC)/tenofovir DF (TDF) and efavirenz (EFV) compared to fixed dose zidovudine/lamivudine (CBV) and EFV in antiretroviral treatment-naïve patients. Program and Abstracts of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, Australia (2007) (Abstract WEPEB029).
12. Campbell T, Smeaton L, Kumarasamy N et al. Efficacy and safety of EFV with either co-formulated 3TC/ZDV or FTC/TDF for initial treatment of HIV-1-infected men and women in diverse multinational settings: ACTG PEARLS Study. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 27 February-2 March 2011 (Abstract 149LB).
13. Sax P, Tierney C, Collier A et al. Abcavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N. Engl. J. Med. 361, 2230-2240 (2009).
14. Grant P, Tierney C, Katzenstein D et al. Association of baseline viral load, CD4 count, and week 4 virologic response with virologic failure in ACTG study A5202. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 27 February-2 March 2011 (Abstract 535).
15. Post FA, Moyle GJ, Stellbrink HJ, Domingo P, Podzamczer D. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J. Acquir Immune Defic. Syndr. 55(1), 49-57 (2010).
16. Sabin CA, Worm SW, Weber R et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the DAD Study: a multi-cohort collaboration. Lancet 371, 1417-1426 (2008).
17. SMART/INSIGHT and the D:A:D Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 22(14), F17-F24 (2008).
18. Ding X, Andraca-Carrera E, Cooper C et al. No association of myocardial infarction with ABC use: an FDA meta-analysis. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 27 February-2 March 2011 (Abstract 808).
19. van Leth F, Phanuphak P, Ruxrungtham K et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study. Lancet 363(9417), 1253-1263 (2004).
20. + T-cell counts. Antiviral Ther. 12(3), 325-333 (2007).
21. Wit FW, Kesselring AM, Gras L, Richter C et al. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study. Clin. Infect. Dis. 46(6), 933-940 (2008).
22. Schouten JT, Krambrink A, Ribaudo HJ et al. Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095. Clin. Infect. Dis. 50(5), 787-791 (2010).
23. Scourfield A, Waters L, Jackson A et al. Absence of skin hypersensitivity in subjects switching to etravirine with undetectable plasma HIV RNA: a randomized prospective study HIV Med. 12(Suppl. 1), (2011) (Abstract P102).
24. Munoz-Moreno JA, Fumaz CR, Ferrer MJ et al. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review. AIDS Rev. 11(2), 103-109 (2009).
25. Waters L, Fisher M, Winston A et al. A Phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine. AIDS 25(1), 65-71 (2011).
26. Nguyen A, Calmy A, Delhumeau C et al. A randomized crossover study to compare efavirenz and etravirine treatment. AIDS 25(1), 57-63 (2011).
27. Nelson M, Stellbrink H-J, Podzamczer D et al. A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population. AIDS 25(3), 335-340 (2011).
28. Molina JM, Andrade-Villanueva J, Echevarria J et al. Once-daily atazanavir/ ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J. Acquir Immune Defic Syndr. 53(3), 323-332 (2010).
29. Orkin C, DeJesus E, Khanlou H et al. ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPVr) in treatment-naive HIV-1-infected adults. Abstracts of the Tenth International Congress on Drug Therapy in HIV Infection. J. Intl AIDS Soc. 13(Suppl. 4), P43 (2010).
30. Riddler SA, Haubrich RH, DiRenzo AG et al. AIDS Clinical Trials Group Study A5142 Team. Class-sparing regimens for initial treatment fo HIV-1 infections. N. Engl. J. Med. 358(20), 2095-2106 (2008).
31. Sierra-Madero J, Villasis-Keever A, Mendez P et al. A prospective randomized open label trial of efavirenz vs lopinavir/ritonavir based HAART among HIV infected naive individuals presenting for care with CD4 + cell counts <200 cell/mm3 in Mexico, Abstracts of the Seventeenth International AIDS Conference, 2008 Mexico City Mexico Abstract TUAB0104).
32. Ribaudo HJ, Kuritzkes DR, Lalama CM et al. Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts. J. Infect. Dis. 197(7), 1006-1010 (2008).
33. Daar ES, Tierney C, Fischl MA et al. for the AIDS Clinical Trials Group Study A5202 Team. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1: a randomized trial. Ann. Intern. Med. 154(7), 445-456 (2011).
34. Smith K, Tierney C, Daar E et al. Association of race/ethnicity and sex on outcomes in ACTG Study A5202. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 27 February-2 March 2011 (Abstract 536).
35. Rockstroh J, Lennox J, DeJesus E et al. Raltegravir (RAL) demonstrates durable virologic suppression and superior immunologic response with a favorable metabolic profile through 3 years of treatment (Tx), 156 week (Wk) results from STARTMRK. Presented at: 18th Conference on Retroviruses and Opportunistic Infections 2011. Boston, MA, USA, 27 February-2 March 2011 (Poster #542).
36. Molto J, Valle M, Back D et al. Plasma and intracellular (PBMCs) pharmacokinetics of once-daily raltegravir (800 mg) in HIV-infected patients. Antimicrob. Agents Chemother. DOI: 10.1128/AAC.00789-10 (2010) (Epub ahead of print).
37. Eron J, Rockstroh J, Reynes J et al. QDMRK, a Phase III study of the safety & efficacy of once daily (QD) versus twice daily (BID) raltegravir (RAL) in combination therapy for treatment-naive HIV-infected patients. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 27 February-2 March 2011.
38. Saag M, Ive P, Heera J et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine/ lamivudine), for the treatment of antiretroviral naive subjects infected with R5 HIV-1: week 48 results of the MERIT study. Presented at: 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. Sydney, Australia, 22-25 July 2007 (Abstract WESS104).
39. Cooper DA, Heera J, Goodrich J et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J. Infect. Dis. 201, 803-813 (2010).
40. Staszewski S, Pozniak AL, Gallant J et al. Renal safety profile of tenofovir DF (TDF)-containing compared to non-TDF-containing regimens in antiretroviral-naive patients with mild renal impairment or hypertension and/or diabetes mellitus. Presented at: 8th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, 12-16 November 2006.
41. Delfraissy JF, Flandre P, Delaugerre C et al. MONARK Trial (Monotherapy Antiretroviral Kaletra), 48-week analysis of lopinavir/ritonavir (LPV/r) monotherapy compared to LPV/r + zidovudine/ lamivudine (AZT/3TC) in antiretroviral-naive patients. Program and Abstracts of the XVI International AIDS Conference. Toronto, ON, Canada, 13-18 August 2006 (Abstract THLB0202).
42. Joly V, Flandre P, Meiffredy V et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 16(18), 2447-2454 (2002).
43. Patterson P, Krolewiecki A, Tomaka F, Miralles D, Spinosa S, Cahn P. A Phase II, open-label trial in treatment-naive, HIV-1-infected subjects who received DRV/RTV as induction monotherapy. Presented at: 12th European AIDS Conference. Cologne, Germany, 11-13 November (Abstract PS4/4).
44. Arribas JR, Pulido F, Delgado R et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression. A randomized, controlled, open label, pilot, clinical trial (OK Study), 48 weeks analysis. Program and Abstracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil, 24-27 July 2005 (Abstract WePe12.3C05).
45. Valantin MA, Duvivier C, Lambert-Niclot S et al. Lonγ-term efficacy of DVR/r monotherapy in patients with HIV-1 viral suppression in the MONOI-ANRS 136 study: results at 96 weeks. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 27 February-2 March 2011 (Abstract 534).
46. Rieger A, Banhegyi D, Schmidt W et al. The MONET trial 96 week analysis: darunavir/r monotherapy versus darunavir/r + 2 NRTIs, for patients with HIV RNA <50 copies/ml at baseline. Presented at: XVIII Internationa AIDS Conference. Vienna, Austria, 18-23 July 2010 (Abstract TBLBB209).
47. Squires KE, Young B, Dejesus E et al. Similar efficacy and tolerability of atazanavir compared with atazanavir/ ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/ lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. AIDS 24(13), 2019-2027 (2010).
48. Kozal M, Lupo S, DeJesus E et al. The SPARTAN study: a pilot study to assess the safety and efficacy of an investigational NRTI- and RTV-sparing regimen of atazanavir (ATV) experimental dose of 300 mg BID plus raltegravir (RAL) 400 mg BID (ATV+RAL) in treatment-naive HIV-infected subjects. Presented at: 18th International AIDS Conference. Vienna, Austria, 18-23 July 2010 (Abstract THLBB204).
49. Reynes J, Lawal A, Pulido F et al. Lopinavir/ritonavir combined with raltegravir demonstrated similar antiviral efficacy and safety as lopinavir/ritonavir combined with tenofovir disoproxil fumarate/emtricitabine in treatment-naive HIV-1 infected subjects. Presented at: XVIII International AIDS Conference. Vienna, Austria, 18-23 July 2010.
50. Soto-Malave R, Lawall A, Reynes J et al. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral naive subjects: 96 weeks efficacy and safety results of the PROGRESS study. Presented at: XV Congreso Panamericano De Infectología Punta del Este. Uruguay, 7-11 April 2011.
51. Tungsiripat M, Kitch D, Glesby MJ et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS 24(11), 1781-1784 (2010).
52. Randell PA, Jackson AG, Zhong L, Yale K, Moyle GJ. The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers. Antivir Ther. 15(2), 227-233 (2010).
53. Taiwo B, Zheng S, Gallien S et al. Results from a single arm study of DRV/r + RAL in treatment-naive HIV-1-infected patients (ACTG A5262). Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 27 February-2 March 2011 (Abstract 551).
54. Mills A, Mildvan D, Podzamczer D et al. Safety and immunovirological activity of once daily maraviroc (MVC) in combination with ritonavir-boosted atazanavir (ATV/r) compared to emtricitabine 200 mg/tenofovir 300 mg once daily (TDF/FTC) + ATV/r in treatment-naive patients infected with CCR5-tropic HIV-1 (Study A4001078), a week 24 planned interim analysis. Presented at: XVIII International AIDS Conference. Vienna, Austria, 18-23 July 2010.
55. Markowitz M, Zolopa A, Ruane P et al. GS-7340 demonstrates greater declines in HIV-1 RNA than TDF during 14 days of monotherapy in HIV-1-infected subjects. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 27 February-2 March 2011 (Abstract 152LB).
56. Cohen C, Molina J, Cahn P et al. Pooled week 48 efficacy and safety results from ECHO and THRIVE, two double-blind, randomised, Phase III trials comparing TMC278 versus efavirenz in treatment-naive, HIV-1-infected patients. Presented at: XVIII International AIDS Conference. Vienna, Austria, 18-23 July 2010.
57. van't Klooster G, Verloes R, Baert L et al. Lonγ-acting TMC278, a parenteral depot formulation delivering therapeutic NNRTI concentrations in preclinical and clinical settings. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 3-6 February 2008.
58. Fatkenheuer G, Staszewski S, Plettenburg A et al. Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients. AIDS 23(16), 2115-2122 (2009).
59. Corbau R, Mori J, Phillips C, Fishburn L et al. Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against druγ-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 54(10), 4451-4463 (2010).
60. Elion R, Gathe J, Rashbaum B et al. The single-tablet regimen of (EVG/COBI/ FTC/TDF; Quad) maintains a high rate of virologic suppression, and cobicistat (COBI) is an effective pharmacoenhancer through 48 weeks. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010). Boston, MA, USA, 12-15 September 2010.
61. Rockstroh J, Felizarta F, Maggiolo F et al. Once-daily S/GSK1349572 combination therapy in antiretroviral-naive adults: rapid and potent 24-week antiviral responses in SPRINγ-1 (ING112276). Presented at: HIV10. Glasgow, UK, 7-11 November 2010.
62. Eron J, Kumar P, Lazzarin A et al. DTG in subjects with HIV exhibiting RAL resistance: functional monotherapy results of VIKING Study cohort II. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 27 February-2 March 2011 (Abstract 151LB).
63. Martin D, Kawase M, Asahi S et al. TBR-652 absorption, distribution, metabolism, and excretion profile in rats, dogs, monkeys, and humans. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 27 February-2 March 2011 (Abstract 627).
64. Nettles R, Schurmann D, Zhu L et al. Pharmacodynamics, safety, and pharmacokinetics of BMS-663068: a potentially first-in-class oral HIV attachment inhibitor. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 27 February-2 March 2011 (Abstract 49).
65. Lalezari J, Mitsuyasu R, Deeks S et al. Successful and persistent engraftment of ZFN-M-R5-D autologous CD4 T cells (SB-728-T) in aviremic HIV-infected subjects on HAART. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 27 February-2 March, 2011 (Abstract 46).
66. Wilen C, Wang J, Tilton J et al. Creating an HIV-resistant immune system: using CXCR4 ZFN to edit the human genome. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 27 February-2 March, 2011 (Abstract 46).
67. Abrams D, Levy Y, Losso MH et al. Interleukin-2 therapy in patients with HIV infection. N. Engl. J. Med. 361(16), 1548-1559. (2009).
68. Levy Y, Lacabaratz C, Weiss L et al. Enhanced T cell recovery in HIV-1- infected adults through IL-7 treatment. J. Clin. Invest. 119(4), 997-1007 (2009).
69. Paton N; HCQ-01 Trial Group. Effects of hydroxychloroquine on immune activation in ART- naive patients: a 48-week randomised, double-blind, placebo-controlled trial. Presented at: 6th IAS Conference. Rome, Italy, 17-20 July 2011 (Poster MOPE269).
70. Piconi S, Parisotto S, Capetti A et al. Immunomodulatory effects of hydroxychloroquine in HIV-infected ART-treated immunological non-responders. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston MA, USA, 27 February-2 March 2011 (Abstract 382).
71. + cell rises in HIV-infected patients. PLoS ONE 5(10), e13188 (2010).
72. De Clercq E. Antivirals and antiviral strategies. Nat. Rev. Microbiol. 2(9), 704-720 (2004).